CA2364209A1 - 49 proteines secretees humaines - Google Patents

49 proteines secretees humaines Download PDF

Info

Publication number
CA2364209A1
CA2364209A1 CA002364209A CA2364209A CA2364209A1 CA 2364209 A1 CA2364209 A1 CA 2364209A1 CA 002364209 A CA002364209 A CA 002364209A CA 2364209 A CA2364209 A CA 2364209A CA 2364209 A1 CA2364209 A1 CA 2364209A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
sequence
human
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002364209A
Other languages
English (en)
Inventor
Craig A. Rosen
Steven M. Ruben
George Komatsoulis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2364209A1 publication Critical patent/CA2364209A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouvelles protéines sécrétées humaines et des acides nucléiques contenant les régions codantes des gènes qui codent pour ces protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps et des procédés recombinants permettant de produire des protéines sécrétées humaines. L'invention concerne en outre des méthodes de diagnostic et de traitement permettant de diagnostiquer et de traiter les maladies, troubles et/ou états pathologiques associés à ces nouvelles protéines sécrétées humaines.
CA002364209A 1999-03-26 2000-03-23 49 proteines secretees humaines Abandoned CA2364209A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12660199P 1999-03-26 1999-03-26
US15437399P 1999-09-17 1999-09-17
US17606400P 2000-01-14 2000-01-14
US60/126,601 2000-01-14
US60/176,064 2000-01-14
US60/154,373 2000-01-14
PCT/US2000/007677 WO2000063230A2 (fr) 1999-03-26 2000-03-23 49 proteines secretees humaines

Publications (1)

Publication Number Publication Date
CA2364209A1 true CA2364209A1 (fr) 2000-10-26

Family

ID=27383444

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002364209A Abandoned CA2364209A1 (fr) 1999-03-26 2000-03-23 49 proteines secretees humaines

Country Status (5)

Country Link
EP (1) EP1171462A2 (fr)
JP (1) JP2002541833A (fr)
AU (1) AU6745700A (fr)
CA (1) CA2364209A1 (fr)
WO (1) WO2000063230A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573095B1 (en) 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
CA2398396A1 (fr) * 2000-01-25 2001-08-02 Hyseq, Inc. Methodes et matieres concernant des polypeptides et polynucleotides similaires a alpha de facteur de croissance de transformation
AU2001260847A1 (en) * 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
ATE350396T1 (de) * 2001-05-25 2007-01-15 Nymox Corp Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
CN100475843C (zh) 2001-07-19 2009-04-08 尼莫克斯股份有限公司 有效***和其它需要除去或破坏细胞的疾病的肽
EP1847550A3 (fr) * 2001-07-19 2008-01-09 Nymox Corporation Peptides actives dans le traitement des tumeurs et autre conditions requérant la suppression ou la destruction de cellules
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
KR100535543B1 (ko) * 2002-09-13 2005-12-08 현대자동차주식회사 스로틀 밸브 동결 방지장치
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor

Also Published As

Publication number Publication date
WO2000063230A2 (fr) 2000-10-26
AU6745700A (en) 2000-11-02
EP1171462A2 (fr) 2002-01-16
WO2000063230A3 (fr) 2001-02-08
JP2002541833A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
CA2368068A1 (fr) 27 proteines humaines secretees
CA2382185A1 (fr) 48 proteines secretees humaines
CA2364209A1 (fr) 49 proteines secretees humaines
CA2368927A1 (fr) Quarante-cinq proteines humaines secretees
CA2387696A1 (fr) 48 proteines humaines secretees
CA2364630A1 (fr) 50 proteines humaines secretees
CA2365223A1 (fr) Proteines humaines secretees (46)
CA2368281A1 (fr) 50 proteines humaines secretees
CA2368467A1 (fr) 50 proteines humaines secretees
CA2391364A1 (fr) 47 proteines humaines secretees
CA2364635A1 (fr) 47 proteines humaines secretees
CA2365522A1 (fr) 48 proteines secretees humaines
CA2368302A1 (fr) 49 proteines secretees par un etre humain
CA2391361A1 (fr) 47 proteines secretees humaines
CA2370441A1 (fr) 50 proteines humaines secretees
CA2390946A1 (fr) 49 proteines secretees humaines
CA2368442A1 (fr) 48 proteines humaines secretees
CA2365247A1 (fr) Proteines humaines secretees (49)
CA2368374A1 (fr) 47 proteines humaines secretees
CA2368719A1 (fr) Cinquante proteines humaines secretees
CA2364650A1 (fr) Proteines humaines secretees (50)
CA2371172A1 (fr) 50 proteines humaines secretees
CA2368916A1 (fr) 49 proteines humaines secretees
CA2382769A1 (fr) 42 proteines humaines secretees
CA2367620A1 (fr) Proteines humaines secretees (47)

Legal Events

Date Code Title Description
FZDE Dead